文献速递前列腺癌

MRI可疑区超声特征可预测融合靶向活检中临床显著前列腺癌

The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI-ultrasound fusion-targeted biopsy.
PubMed 文献 · BJU Int · 2018-11-30

该前瞻性队列纳入1058例接受MRI-超声融合靶向活检的男性,由术者对MRI感兴趣区(ROI)的超声表现分级为0、1、2级。672例分析显示,超声分级越高,任何前列腺癌和Gleason评分≥7癌的检出率均显著升高,且超声分级是Gleason评分≥7癌的独立预测因素。

要点

  • MRI ROI处超声低回声区分级越高,前列腺癌检出率越高。
  • 超声分级可独立预测Gleason评分≥7前列腺癌。
  • 融合靶向活检时识别ROI超声特征有助于风险分层。

核心结论

  • MRI感兴趣区部位的超声表现可独立预测Gleason评分≥7前列腺癌的可能性,边界清晰的低回声区者风险更高。

研究设计与样本

  • 前瞻性纳入2011年7月至2017年6月由单一术者行MRI-超声融合靶向活检(联合或不联合系统活检)的1058例男性,最终672例纳入分析。
  • 由单一放射科医生对每个MRI ROI进行可疑评分,术者前瞻性评估ROI处超声低回声区并分级为0、1、2级(无、边界不清、边界清晰)。

主要发现

  • 672例男性总体前列腺癌检出率为61.2%,Gleason评分≥7癌检出率为39.6%。
  • 超声分级0、1、2级的任何前列腺癌检出率分别为46.2%、58.6%、76.0%(P < 0.001)。
  • 超声分级0、1、2级的Gleason评分≥7癌检出率分别为18.7%、35.2%、61.1%(P < 0.001)。
  • 仅行MRI-超声融合靶向活检时,超声分级0、1、2级的Gleason评分≥7癌检出率分别为12.8%、25.7%、52.0%(P < 0.001)。
  • 多因素回归显示超声分级、前列腺特异性抗原密度和MRI可疑评分可预测靶向活检中Gleason评分≥7前列腺癌。

关键数值与推荐

  • 超声分级0、1、2级分别代表无低回声区、边界不清的低回声区、边界清晰的低回声区。
  • 在MRI可疑评分2-4分的男性中,单因素分析显示超声分级可预测Gleason评分≥7癌检出率。

临床怎么用

  • 行MRI-超声融合靶向活检时,应关注MRI ROI处是否存在超声低回声区及其边界清晰度,以辅助判断临床显著前列腺癌风险。

局限性

  • 单术者操作,超声评估可能存在主观性。
  • 部分患者联合系统活检,可能影响检出率归因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether the presence of an ultrasound hypoechoic region at the site of a region of interest (ROI) on magnetic resonance imaging (MRI) results in improved prostate cancer (PCa) detection and predicts clinically significant PCa on MRI-ultrasonography fusion-targeted prostate biopsy (MRF-TB). MATERIALS AND METHODS: Between July 2011 and June 2017, 1058 men who underwent MRF-TB, with or without systematic biopsy, by a single surgeon were prospectively entered into an institutional review board-approved database. Each MRI ROI was identified and scored for suspicion by a single radiologist, and was prospectively evaluated for presence of a hypoechoic region at the site by the surgeon and graded as 0, 1 or 2, representing none, a poorly demarcated ROI-HyR, or a well demarcated ROI-HyR, respectively. The interaction of MRI suspicion score (mSS) and ultrasonography grade (USG), and the prediction of cancer detection rate by USG, were evaluated through univariate and multivariate analysis. RESULTS: For 672 men, the overall and Gleason score (GS) ≥7 cancer detection rates were 61.2% and 39.6%, respectively. The cancer detection rates for USGs 0, 1 and 2 were 46.2%, 58.6% and 76.0% (P < 0.001) for any cancer, and 18.7%, 35.2% and 61.1% (P < 0.001) for GS ≥7 cancer, respectively. For MRF-TB only, the GS ≥7 cancer detection rates for USG 0, 1 and 2 were 12.8%, 25.7% and 52.0%, respectively (P < 0.001). On univariate analysis, in men with mSS 2-4, USG was predictive of GS ≥7 cancer detection rate. Multivariable regression analysis showed that USG, prostate-specific antigen density and mSS were predictive of GS ≥7 PCa on MRF-TB. CONCLUSIONS: Ultrasonography findings at the site of an MRI ROI independently predict the likelihood of GS ≥7 PCa, as men with a well-demarcated ROI-HyR at the time of MRF-TB have a higher risk than men without.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Press B, Rosenkrantz AB, Huang R, et al. The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI-ultrasound fusion-targeted biopsy. BJU Int. 2018. PMID: 30415476. doi:10.1111/bju.14615

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。